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ABSTRACT 
BACKGROUND  
Remnant-like lipoprotein particle cholesterol (RLP-c) is a highly 
atherogenic factor. RLP-c induces endothelial dysfunction and is associated 
with hyperinsulinemia. The present study was designed to determine 
whether high plasma RLP-c levels predispose to the development of 
hypertension in subjects with normal blood pressure (BP).  
METHODS 
A total of 1,485 subjects aged over 40 years in a Japanese Cohort of the 
Seven Countries Study received health examinations. We examined BP, 
anthropometric parameters, and blood chemistries including fasting RLP-c 
levels. RLP-c levels were measured by an immune-separation method. We 
excluded from the analysis 676 subjects who had hypertension 
(BP≥140/90mmHg), or were on antihypertensive medication, and/or on 
antihyperlipidemic medication at baseline. Ten years later, 681 subjects 
were re-examined. 
RESULTS 
Of 681 normotensives at baseline, 303 subjects had developed hypertension 




Kasahara A et al., AJH-D-12-282. R-3 final 
the subjects who developed hypertension than in those who remained 
normotensive (3.7±1.9 vs. 3.3±1.6 mg/dl). Multivariate logistic regression 
analysis demonstrated that baseline RLP-c was a significant factor for 
incident hypertension after adjustments for homeostasis model assessment 
(HOMA) index and other hypertension related factors [odds ratio, 1.05 
(95% CI; 1.00-1.10); p=0.04].  
CONCLUSION 
A high level of plasma RLP-c in normotensive subjects may predispose to 
the development of hypertension in a population of community-dwelling 
Japanese. 
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INTRODUCTION 
Remnant-like lipoprotein particle cholesterol (RLP-c) derived from 
triglycerides-rich lipoprotein is taken up by macrophages and causes foam 
cell formation in vitro,1 and is considered to be highly atherogenic.2-4 
Elevated plasma RLP-c levels are associated with endothelial 
dysfunction5-9 and hyperinsulinemia.10,11 Endothelial dysfunction and 
hyperinsulinemia may be associated with the development of 
hypertension.12-14 Thus, it is considered that elevated plasma RLP-c levels 
may be associated with incident hypertension. In fact, elevated RLP-c was 
associated with hypertension in a general population without diabetes15 and 
in patients with preeclampsia.16 However, because of the cross sectional 
nature of the previous studies, it was not clear whether high RLP-c levels in 
subjects with normal blood pressure (BP) is associated with incident 
hypertension. Accordingly, we conducted a longitudinal study in subjects in 
a general population without hypertension at baseline to evaluate the 
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Study population. 
A periodic epidemiological survey was performed in 1999 in a rural 
farming community located in the south-west part of Japan (Tanushimaru 
town). An earlier cohort in Tanushimaru was a part of the Seven Countries 
Study.17 As reported previously, the demographic backgrounds of the 
subjects in this area were similar to those of the general Japanese 
population.18 We examined 1,485 persons (602 males and 883 females) 
over the age of 40 years. We excluded 678 subjects from the analysis who 
had hypertension (BP≥140/90mmHg) and/or were on antihypertensive 
medications or on antihyperlipidemic medications, and/or had RLP-c 
≥100mg/dl (n=2) at baseline. 
A cross-sectional analysis was performed in 807 subjects. Ten years 
later, in 2009, we conducted a follow-up examination in the same cohort. 
Of 807 subjects, 65 (8.1%) had died, and 61 (7.6%) refused the 
re-examination. Consequently, 681 subjects (248 males and 433 females) 






Kasahara A et al., AJH-D-12-282. R-3 final 
A general medical history including smoking, alcohol intake and current 
medication, was obtained. Height and weight were measured, and body 
mass index (BMI) was calculated as an index of obesity. Waist 
circumference was measured at the level of the umbilicus in the standing 
position. BP was measured twice with the subjects in the supine position. 
The second BP was adopted and systolic and fifth-phase diastolic pressures 
were used for analysis. Blood was drawn from the antecubital vein in the 
morning after a 12-h fast for determinations of lipids profiles (RLP-c, 
triglycerides, high-density lipoprotein cholesterol [HDL-c], and low- 
density lipoprotein cholesterol [LDL-c]), fasting plasma glucose (FPG), 
insulin, hemoglobin A1c [HbA1c (NGSP)], blood urea nitrogen (BUN), 
creatinine, von Willebrand Factor (vWF), and fibrinogen levels. Fasting 
blood samples were centrifuged within 1 hour after collection. Creatinine 
was measured by enzymatic method. vWF was measured by a 
double-antibody ELISA and fibrinogen was measured by high-performance 
liquid chromatography (HPLC). Serum RLP-c was measured by 
immune-separation technique19 (using an immune-affinity gel containing 
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Five milligrams of anti-apo B-100 and anti-apo A-1 IgG each were coupled 
to 1 ml of CNBr-Sepharose 4B gel, according to the recommendations of 
the manufacturer. Then, the remaining active sites on the gels were blocked 
with 0.2 M glycine. Before use the gels were conditioned with calf serum 
for 1 hour at room temperature with gentle shaking to reduce non-specific 
binding and washed with 1.0 M acetic acid/0.5 M NaCl. This procedure 
was repeated twice.19 Intra- and inter-assay coefficients of variation of 
RLP-c in the commercially available laboratory that performed the assays 
(The Kyodo Igaku Laboratory, Fukuoka, Japan) were 7.6% and 7.8%, 
respectively. A homeostasis model assessment (HOMA) index [FPG 
(mg/dl) × insulin (μU/ml)/405] was calculated from fasting glucose and 
insulin levels as a marker of insulin resistance.20 Estimated glomerular 
filtration rate (eGFR) was calculated using the Modification of Diet in 
Renal Disease (MDRD) study equation modified with a Japanese 
coefficient21: eGFR (mL/minute/1.73m2) = 194×Age-0.287×Serum 
creatinine-1.094 (if female×0.739). Hypertensives were defined as those 
with BP≥140/90mmHg and/or those receiving antihypertensive medication.  
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Medical Association and by the mayor, as well as by the ethics committee 




Results are presented as means±standard deviation (SD), unless otherwise 
specified. Because of skewed distributions, natural logarithmic 
transformations were performed for RLP-c, triglycerides, insulin and 
HOMA index. These variables were represented as original scale after 
analysis by log (natural) transformed values in tables. In Tables 1, 2 and 3, 
values of RLP-c, triglycerides, insulin and HOMA index are presented as 
geometric mean and range. The χ2 test was used for categorical parameters 
to test differences between groups. Sex, smoking habits, and alcohol intake 
were used as dummy variables. Univariate logistic regression analysis was 
performed for factors related to the development of hypertension. We 
estimated odds ratios and their 95% confidence intervals per 1-unit 
(approximately 1 SD) increase in the variables. The odds ratios for RLP-c, 
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increase of the levels. Multiple logistic regression analysis was performed 
to determine independent parameters for development of hypertension after 
adjusting for age, sex, and confounding factors. Statistical significance was 
defined as p<0.05. All statistical analyses were performed using the SAS 
system (Release 9.3; SAS Institute, Cary, NC). 
 
RESULTS 
Table 1 shows the baseline characteristics of the 681 normotensive subjects 
in 1999 stratified by gender. As is apparent from the table, the enrolled 
subjects had almost normal mean values of risk factors and other variables. 
Mean RLP-c level at baseline was 3.4±1.8mg/dl. RLP-c level was 
significantly higher (p<0.01) in males than in females. Table 2 shows 
results of uni- and multi-variate regression analyses for the cross-sectional 
correlates with baseline RLP-c levels. Multivariate analysis showed that 
HOMA index, LDL-c, HDL-c (inversely), total cholesterol/HDL-c ratio 
and triglycerides were significantly associated with RLP-c. Table 3 shows 
univariate logistic regression analysis performed for predictors of the 
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systolic and diastolic BPs, BMI, waist circumference, HOMA index, and 
triglycerides were significantly associated with the development of 
hypertension. Table 4 shows multivariate logistic regression analysis 
performed for predictors of the development of hypertension after 
adjustments for confounding factors. A significant (p=0.04) odds ratio for 
plasma RLP-c level was observed in the final model (model 5) [1.05 (95% 
CI: 1.00-1.10)] for the development of hypertension (adjusted for baseline 
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DISCUSSION 
Based on known aspects of the function of plasma RLP-c, we hypothesized 
that a high level of RLP-c could predict the development of hypertension. 
RLP was an independent predictor for the development of hypertension 
after adjustments for other lipid profiles. Our results are consistent with our 
hypothesis that high levels of RLP-c were associated with the development 
of hypertension after 10 years in normotensive subjects at baseline. This 
study is the first to demonstrate a significant association between high 
plasma levels of RLP-c and the development of hypertension in a general 
population.  
Several mechanisms could explain the association between RLP-c 
and development of hypertension. Because hypertension is associated with 
endothelial dysfunction and because preexisting endothelial function will 
precede hypertension, RLP-c induced endothelial dysfunction may be one 
such mechanism.5-9 In order to examine the contribution of endothelial 
dysfunction to the development of hypertension, we measured two serum 
markers of endothelial dysfunction, von Willebrand factor22,23 and 
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factors (Table 3). However, from the present study, we cannot rule out the 
possibility that endothelial dysfunction induced by RLP-c contributed to 
the development of hypertension because we had no data from more direct 
and reliable measures for endothelial dysfunction like responses to 
acetylcholine measured by the venous occlusion plethysmograph.26-29 
Prospective studies13,14 have shown that increased insulin 
concentration predisposes to the development of hypertension. 
Hyperinsulinemia causes sympathetic activation by acting on the brain and 
impairs sodium secretion from the kidney,30 leading to hypertension.31 It 
has been reported that elevated RLP-c levels are associated with 
hyperinsulinemia or insulin resistance.10,11,32,33 In fact, our multivariate 
analysis of the baseline data demonstrated a significant association between 
RLP-c and HOMA index, a marker of insulin resistance. (Table 2). Thus, 
another possible explanation of the relationship between RLP-c and 
development of hypertension may be hyperinsulinemia or insulin resistance. 
In this study, we determined baseline factors associated with the 
development of hypertension. Besides well-known factors like age, BP and 
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for the development of hypertension (Table 3), consistent with previous 
reports.13,14,34 Thus, our study appears to suggest that insulin resistance may 
underlie the association between RLP-c and the development of 
hypertension. However, our detailed analysis denied this possibility and 
suggested that RLP-c predicted the development of hypertension, 
independent of insulin resistance (Table 4). 
The issue of lipid control and risk of hypertension is interesting. 
Meta-analysis of 20 randomized, controlled trials showed a small but 
statistically significant reduction of systolic BP with statin therapy.35 Some 
review articles also supported the notion that statin may reduce blood 
pressure.36,37 Moreover, it was reported that bezafibrate reduced blood 
pressure in patients with hypertriglyceridemia.38 Although it was not 
reported whether the blood pressure reduction was ascribed to RLP-c 
reduction, it may be feasible to consider that lipid lowering therapy reduces 
blood pressure. 
 
Study Limitations and Perspective 
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follow-up because of death or refusal to participate in re-examination. 
Accordingly, we limited the analysis to subjects for whom all baseline and 
follow-up data were available. Second, the results of this study do not 
necessarily apply to other populations of different ethnicity. Third, we 
performed follow-up examination only once after 10 years. Thus we were 
not able to do Cox`s regression analysis. A final limitation was the lack of 
data of plasma RLP-c at follow-up. Nonetheless, this study suggests that 
plasma RLP-c plays a key role in the development of hypertension. This is 
the perspective of the present study. 
In conclusion, the present study demonstrated that a high level of 
plasma RLP-c predicted the development of hypertension 10 years later in 
normotensive subjects at baseline. High level of plasma RLP-c may 
predispose to the development of hypertension. 
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Table 1. Characteristics of 681 subjects with normal blood pressure at baseline 
 
Parameters†                      Males             Females          Total 
Total No.                           248               433           681 
Age (years)                   60.3±10.1       57.6±9.7      58.6±9.9 
Sex (%)                         248 (36.4)        433 (63.6)      681 (100) 
RLP-cholesterol (mg/dl)‡           3.7              3.3           3.4 
Range (min-max)           0.2-57.7          0.5-59.4       0.2-59.4 
  BMI (kg/m2)                 23.0±2.8        22.7±3.2      22.8±3.1 
  Waist circumference (cm)      80.9±8.2        72.0±7.9      75.2±9.0 
  Systolic BP (mmHg)          121.7±10.5      118.0±12.1    119.4±11.7 
  Diastolic BP (mmHg)          75.5±7.8        71.9±8.4      73.2±8.4 
  Glucose (mg/dl)             98.0±15.8       93.5±13.1     95.1±14.3 
  HbA1c (NGSP) %               5.4±0.7         5.5±0.7       5.5±0.7 
  Insulin (μU/ml)‡                   4.0              4.7           4.4 
    Range (min-max)              1-56             1-52          1-56 
  HOMA index‡                     0.97             1.07          1.03 
    Range (min-max)            0.20-16.3         0.21-12.8      0.20-16.3 
  LDL-cholesterol (mg/dl)      115.0±28.4      126.8±31.4     122.6±30.8 
  HDL-cholesterol (mg/dl)       52.5±12.2       59.6±14.7      57.0±14.3 
  T-chol/HDL-c (mg/dl)           3.8±1.1         3.6±1.0        3.7±1.0 
  Triglycerides (mg/dl)‡             104.4            86.7           92.7 
    Range (min-max)             38-963          28-350         28-963 
  eGFR (ml/min/1.73m2)*       65.0±10.3       63.1±10.2      63.8±10.3 
  von Willebrand factor (%)     143.3±40.3      137.9±43.0     139.9±42.1 
  Fibrinogen (mg/dl)          302.7±52.8      311.7±59.3     308.5±57.1 
  Smoking (n: yes, %)            53 (21.4)         4 (0.9)          57 (8.4) 
  Alcohol intake (n: yes, %)      146 (58.9)        92 (21.2)        238 (34.9) 
*Date are expressed as mean ± SD or %, unless otherwise indicated. Estimated GFR 
was calculated by the Modification of Diet in Renal Disease (MDRD) study equation. 
†Abbreviations; BMI, body mass index; BP, blood pressure; HOMA index, homeostasis 
model assessment index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
T-chol, Total cholesterol; HDL-c, HDL-cholesterol; eGFR, estimated glomerular 
filtration rate 
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Table 2. Univariate and multivariate regression analyses for correlates of plasma 
RLP-cholesterol level at baseline 
                   
Univariate                   Multivariate 
Parameters‡                 β  p value               β  p value 
Age (years)                -0.002   0.56              -0.003    0.44 
Sex                      -0.082   0.03              -0.014    0.75 
BMI (kg/m2)               0.231  <0.01               0.003    0.74 
Waist circumference (cm)    0.264  <0.01               0.002    0.61 
Systolic BP (mmHg)         0.072   0.06               0.002    0.21 
Diastolic BP (mmHg)        0.050   0.20               0.003    0.10 
HbA1c (NGSP) %           0.198  <0.01               0.001    0.96 
HOMA index§             0.309  <0.01               0.055    0.01 
LDL-cholesterol (mg/dl)     0.288  <0.01               0.003    0.01 
HDL-cholesterol (mg/dl)      -0.286  <0.01              -0.017   <0.01 
T-chol/HDL-c                0.329  <0.01               0.291   <0.01 
Triglycerides (mg/dl)§         0.751  <0.01               0.674   <0.01 
eGFR (ml/min/1.73m2)+         -0.068   0.08              -0.001    0.41 
von Willebrand factor (%)      0.042   0.27               0.001    0.87 
Fibrinogen (mg/dl)           0.023   0.55               0.001    0.13 
Smoking (yes)               0.148  <0.01               0.009    0.85 
Alcohol intake (yes)          0.038   0.32               0.026    0.55 
*Males=0, Females=1                                        R2=0.58 
† Estimated GFR was calculated by the Modification of Diet in Renal Disease (MDRD) 
study equation. 
‡ Abbreviations; BMI, body mass index; BP, blood pressure; HOMA index, 
homeostasis model assessment index; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; T-chol, Total cholesterol; HDL-c, HDL-cholesterol;  
eGFR, estimated glomerular filtration rate 
§ Log-transformed values were used in analyses. 
The multivariate analysis was performed only for variables found to have 
statistically significant associations with baseline RLP-c levels in bivariate analysis. 
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Table 3. Univariate regression coefficients for development of hypertension by a logistic 
       regression analyses 
 
Variable (increment )          β      SE     Odds ratio (95% CI)    p value 
Age (10 years)              0.011   0.015    1.02 (1.01-1.04)       0.01 
Sex (Male)                -0.343   0.160    0.71 (0.52-0.97)       0.03 
RLP-cholesterol+ (1.3 times)   0.086   0.059    1.02 (1.01-1.21)       0.01 
Systolic BP (11.7 mmHg)      0.060   0.011    1.06 (1.04-1.09)      <0.01 
Diastolic BP (8.4 mmHg)      0.071   0.014    1.03 (1.02-1.06)      <0.01 
Body mass index (3.1 kg/m2)   0.067   0.025    1.02 (1.01-1.21)      <0.01 
Waist circumference (9 cm)    0.048   0.020    1.06 (1.02-1.10)      <0.01 
eGFR (10.3 ml/min/1.73m2)   -0.028   0.040    0.97 (0.90-1.05)       0.49 
HbA1c (NGSP) (0.7 %)        0.001   0.003    1.00 (0.99-1.01)       0.91 
HOMA index+ (1.5 times)      0.293   0.094    1.34 (1.11-1.61)       0.01 
LDL-cholesterol (30.8 mg/dl)   0.003   0.053    1.00 (0.91-1.11)       0.95 
HDL-cholesterol (14.3 mg/dl)  -0.007   0.008    0.99 (0.98-1.01)       0.33 
T-chol/HDL-c (1.0 mg/dl)      0.016   0.076    1.01 (0.97-1.37)       0.18 
Triglycerides+ (1.1 times)      0.006   0.023    1.05 (1.02-1.09)       0.01 
von Willebrand factor (42.1 %)  0.001   0.002    1.00 (0.99-1.01)       0.91 
Fibrinogen (57.1 mg/dl)       0.001   0.001    1.00 (0.99-1.00)       0.67 
Smoking                   0.241   0.203    1.27 (0.86-1.89)       0.23 
Alcohol intake               0.346   0.195    1.41 (0.97-2.07)       0.08 
*Abbreviations: SE, Standard error, HOMA index, homeostasis model assessment index 
             T-chol, Total cholesterol, HDL-c, HDL-cholesterol 
†These variables are shown in the original scale after analysis using log 
(natural)-transformed values. The odds ratios for these variables are the odds ratio per 
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Table 4. Odds ratios of plasma RLP-cholesterol levels for development of hypertension 
 
Model                    Odds ratio                    p value 
 Unadjusted              1.08 (1.03-1.14)                   0.01 
 Model 1                 1.07 (1.02-1.12)                   0.03 
 Model 2                 1.05 (1.00-1.10)                   0.04 
 Model 3                 1.05 (1.00-1.10)                   0.04 
 Model 4                 1.05 (1.00-1.10)                   0.04 
 Model 5                 1.05 (1.00-1.10)                   0.04 
Odds ratio (95%C.I.) 
Model 1: Adjusted for age and sex 
Model 2: Adjusted for age, sex and systolic BP 
Model 3: Adjusted for age, sex, systolic BP, BMI and waist circumference 
Model 4: Adjusted for age, sex, systolic BP, BMI, waist circumference and HOMA index 
Model 5: Adjusted for age, sex, systolic BP, BMI, waist circumference, HOMA index and 
triglycerides 
 
